Flucloxacillin 2g powder for solution for injection vials
Requires a prescription from a doctor or prescriber
Antibiotic analog of [cloxacillin].
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Flucloxacillin
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Flucloxacillin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Flucloxacillin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Flucloxacillin on the MHRA register
Flucloxacillin 2g powder for solution for injection vials
WHO defined daily dose (DDD)
2 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(9)
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)
Leg ulcer infection: antimicrobial prescribing (NG152)
Impetigo: antimicrobial prescribing (NG153)
Diabetic foot problems: prevention and management (NG19)
Cystic fibrosis: diagnosis and management (NG78)
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)
Neonatal infection: antibiotics for prevention and treatment (NG195)
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 13 · Randomised trials: 6 · 2005–2026
Showing the 50 most relevant studies, sorted by most relevant.
Griffin NA, Epperson AB, Awad ME, et al.
2025
Acute Systemic Antimicrobial Prophylaxis (ASAP) is the standard of care for managing open fractures. There is concern that protocols do not address the modern open fracture bioburden. Online databases were searched to estimate the effect size in reducing the risk of postoperative infections in open fracture management stratified by regimen and fracture classification. 2,031 patients from 17 studies were analyzed. Meta-analysis of Type III open fractures suggested that Flucloxacillin + Benzylpenicillin had a lower infection rate than Cefazolin + Gentamicin; furthermore, the duration of hospitalization was extended by four days with Cefazolin + Gentamicin in Type II/III open fractures. No one antibiotic prophylactic regimen can be recommended over another in the management of open fractures with the current available data. We offer methodological guidelines for future trials that will allow robust evidence for future studies.
Abstract licence: CC BY
E. Wallenburg, R. Brüggemann, J. Roberts, et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021
R. Brindle, O. Williams, P. Davies, et al.
BMJ Open, 2017
2026
- Staphylococcus aureus
- Bacteremia
- Staphylococcal Infections
Michael Quirke, Ronan O’Sullivan, Aileen Mccabe, et al.
European Journal of Emergency Medicine, 2014
Laila F Ibrahim, S. Hopper, F. Orsini, et al.
The Lancet. Infectious diseases, 2019
Joshua S. Davis, John D. Turnidge, Steven Y. C. Tong
International journal of antimicrobial agents, 2018
A. Daly, P. Donaldson, P. Bhatnagar, et al.
Nature Genetics, 2009
M. Monshi, L. Faulkner, Andrew Gibson, et al.
Hepatology, 2013
Shaoning Luo, Y. Lai, Chunxin Liu, et al.
International journal of clinical and experimental medicine, 2015
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
0.75–1 hour
Mechanism
By binding to specific penicillin-binding proteins (PBPs) located inside the bac…
Food interactions
1 warning
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
50–70%
Half-life
0.75–1 hour
Metabolism
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 427 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132
Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269
ATC J01CR50
ATC J01CF05
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Flucloxacillin
Additional database identifiers
Drugs Product Database (DPD)
11348
ChemSpider
20037
BindingDB
50370590
ZINC
ZINC000004102187
GenBank Gene Database
BA000016
GenBank Protein Database
18145626
UniProt Accession
PBPA_CLOPE
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:42
GenAtlas
ABCB11
GeneCards
ABCB11
GenBank Gene Database
AF091582
GenBank Protein Database
3873243
Guide to Pharmacology
778
UniProt Accession
ABCBB_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72